The Complete Blood Count Device Market comprises products used to count and analyze the various cellular components found in blood samples such as RBCs, WBCs, and platelets. Complete Blood Count devices provide crucial insights into a patient’s overall health by detecting abnormalities and disorders related to blood cells. These devices automate the process of blood count testing and delivers results rapidly with improved accuracy. The global adoption of CBC devices has increased due to the rising need for precision diagnosis of blood-related diseases and an aging population prone to chronic illnesses. The Global Complete Blood Count Device Market is estimated to be valued at US$ 4922.18 Mn in 2024 and is expected to exhibit a CAGR of 12.% over the forecast period 2024 to 2030.

Key Takeaways

Key players operating in the Complete Blood Count Device Market are Agilent Technologies, Inc., BD, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Danaher, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN, Merck KGaA, Shimadzu Corporation, Hitachi, Ltd., Bruker, Oxford Instruments, ZEISS International, Genome Medical, Inc., Hamilton Company, and Beckman Coulter, Inc. These players are focusing on developing innovative digital platforms for advanced blood cell analysis.
The growing prevalence of chronic diseases such as cancer, anemia, infections, and cardiovascular diseases has increased the testing volume of complete blood count globally. Moreover, the rising elderly population and lifestyle diseases have further driven the demand for CBC devices in recent years.
The Complete Blood Count Device Market is expanding globally with the increasing healthcare investments in emerging nations for improving diagnostics infrastructure. Major market players are focusing on geographic expansions and strategic partnerships to address unmet needs in developing countries.

Market key Trends

One of the key trends witnessed in the Complete Blood Count Device Market Demand Growth is the shift towards digital pathology platforms enabled with artificial intelligence and machine learning capabilities. This facilitates advanced blood cell analysis, automating morphology classification, and detecting subtle abnormalities. Digital CBC devices offer improved accuracy, precision, and standardized results compared to traditional microscopy methods. Their high-throughput processing abilities are increasing uptake in large commercial labs and hospitals. Additionally, point-of-care CBC devices are gaining popularity due to rapid bedside testing capabilities and portable designs suited for decentralized healthcare settings.

Porter’s Analysis

Threat of new entrants: New players face high initial investment and established brands.
Bargaining power of buyers: Large customer base with bargaining power.
Bargaining power of suppliers: Suppliers have less bargaining power due to availability of substitute products.
Threat of new substitutes: Low due to lack of close substitutes and switching costs.
Competitive rivalry: Intense due to large number of players and price wars.

Geographical regions with highest market value:
North America region holds the highest market share Growth in terms of value due to established healthcare infrastructure and rise in blood related diseases. The United States is the major revenue generating country in this region.

Fastest growing region:

Asia Pacific is expected to witness the highest CAGR during the forecast period due to increasing awareness, healthcare expenditure, large patient pool and improving healthcare infrastructure in emerging countries like China and India. Rising geriatric population susceptible to chronic diseases is also driving the growth.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it